Efficacy and safety of SGLT2 inhibitors in type 1 diabetes after the introduction of an off-label use protocol for clinical practice
Bayona Cebada A, Nattero-Chávez L, et al.
Diabetes Technol Ther. 2020;22(3):208-15
Leggi
Bayona Cebada A, Nattero-Chávez L, et al.
Diabetes Technol Ther. 2020;22(3):208-15
Leggi
Lemelin A, Paré G, Bernard S, Godbout A
Diabetes Technol Ther. 2020;22(3):195-202
Leggi
Sherr JL, Buckingham BA, Forlenza GP, et al.
Diabetes Technol Ther. 2020;22(3):174-84
Leggi
Dauriz M, Morici N, Gonzini L et al.
Am J Med. 2020;133(3):331-339.e2
Leggi
Packer M
American Journal of Medicine. Pub online 12 February 2020
Leggi
Jianhong Z, Xiaoxia Y, Zheng Y, et al.
Lancet Diabetes Endocrinol. 2020;8(3):192-205
Leggi
Kojima T , Hikoso S , Nakatani D, et al.
Am J Cardiol. 2020;125(6):851-9
Leggi
Maddaloni E, Coleman RL, Agbaje O, et al.
Lancet Diabetes Endocrinol. 2020;8(3):206-15
Leggi
Lepore G, Scaranna C, Corsi A, et al.
Diabetes Technol Ther. Pub online 11 February 2020
Leggi
Rodbard D
Diabetes Technol Ther. Pub online 18 February 2020
Leggi